Skip to content
10-K

Annual Report

Immunome, Inc. IMNM

0001193125-26-088172

← back to feed
Filed
Mar 3, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 113.13M sh
Shares Diluted FY 2025 · Dec 31, 2025 87.35M sh
Shares Diluted FY 2025 · Dec 31, 2024 58.64M sh
Capex FY 2025 · Dec 31, 2025 $9.69M
Capex FY 2025 · Dec 31, 2024 $7.17M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$190.92M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$110.79M
Cash And Equivalents FY 2025 · Dec 31, 2025 $653.48M
Cash And Equivalents FY 2025 · Dec 31, 2024 $143.35M
Stockholders Equity FY 2025 · Dec 31, 2025 $634.34M
Stockholders Equity FY 2025 · Dec 31, 2024 $181.17M
Stockholders Equity FY 2025 · Dec 31, 2023 $119.88M
Current Liabilities FY 2025 · Dec 31, 2025 $44.99M
Current Liabilities FY 2025 · Dec 31, 2024 $54.31M
Total Liabilities FY 2025 · Dec 31, 2025 $48.85M
Total Liabilities FY 2025 · Dec 31, 2024 $59.08M
Current Assets FY 2025 · Dec 31, 2025 $660.78M
Current Assets FY 2025 · Dec 31, 2024 $221.34M
Total Assets FY 2025 · Dec 31, 2025 $683.19M
Total Assets FY 2025 · Dec 31, 2024 $240.24M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.43
Eps Diluted FY 2025 · Dec 31, 2024 −$5.00
Eps Basic FY 2025 · Dec 31, 2025 −$2.43
Eps Basic FY 2025 · Dec 31, 2024 −$5.00
Sga Expense FY 2025 · Dec 31, 2025 $43.77M
Sga Expense FY 2025 · Dec 31, 2024 $32.96M
Rd Expense FY 2025 · Dec 31, 2025 $177.29M
Rd Expense FY 2025 · Dec 31, 2024 $129.54M
Net Income FY 2025 · Dec 31, 2025 −$212.39M
Net Income FY 2025 · Dec 31, 2024 −$292.96M
Operating Income FY 2025 · Dec 31, 2025 −$224.11M
Operating Income FY 2025 · Dec 31, 2024 −$305.8M
Revenue FY 2025 · Dec 31, 2025 $6.94M
Revenue FY 2025 · Dec 31, 2024 $9.04M